神术调脾颗粒联合生活方式干预疗法治疗糖耐量受损：一项随机对照试验。
Shenzhu Tiaopi granule combined with lifestyle intervention therapy for impaired glucose tolerance: a randomized controlled trial.
作者信息
Fang Zhaohui, Zhao Jindong, Shi Guobing, Shu Yiqiong, Ni Yingqun, Wang Huan, Ding Lei, Lu Ruimin, Li Jiayun, Zhu Xiaojin, Cheng Senhua, Zhang Xinyi, Liu Yan, Wang Jun, Luo Yuan, Fan Qingyun, Guo Chenglin, Jiang Ting, Wu Qian, Fan Lihong, Ling Hanpeng, Cui Liqun, Luo Yun, Yang Hui, Anderson Robert M
机构信息
Department of Endocrinology, the First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei 230031, Anhui Province, China; Institute of Chinese Medicine Prevention and Therapy Diabetes Mellitus, Anhui Academy of Chinese Medicine, Hefei 230031, Anhui Province, China.
Department of Endocrinology, the First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei 230031, Anhui Province, China; Institute of Chinese Medicine Prevention and Therapy Diabetes Mellitus, Anhui Academy of Chinese Medicine, Hefei 230031, Anhui Province, China.
出版信息
Complement Ther Med. 2014 Oct;22(5):842-50. doi: 10.1016/j.ctim.2014.08.004. Epub 2014 Aug 12.
OBJECTIVE
The purpose of the study was to evaluate the clinical effects of the Shenzhu Tiaopi granule (SZTP) combined with a lifestyle intervention in patients with impaired glucose tolerance (IGT), who also had a spleen deficiency and damp overabundance syndrome (SDDOS).
METHODS
After a one-month washout period, a total of 514 patients were randomly assigned to the control (lifestyle intervention) and experimental (SZTP plus lifestyle intervention) groups, with 257 patients in each group. Patients in the control group received the lifestyle intervention (diet and exercise) for 12 months, while the patients in the experimental group were treated with SZTP plus the lifestyle intervention for 12 months. The Traditional Chinese Medicinal (TCM) symptom scores were observed in each group before and after treatment; the conversion rates from IGT to diabetes mellitus (DM) were also measured.
RESULTS
Following 12 months of treatment, the conversion rate from IGT to DM in the experimental group was significantly lower than in the control group (8.52% vs. 15.28%, P<0.05). A significantly higher number of patients with IGT reverted to normal blood glucose levels in the experimental group than in the control group (42.15% vs. 32.87%, P<0.05). In addition, after following the treatment for 12 months, the TCM symptoms of patients in the experimental group were markedly alleviated, as compared to the control group (P<0.01).
CONCLUSION
The combination of SZTP and lifestyle intervention showed a reduction in the conversion from IGT to DM, and an increase in the conversion from IGT to normal blood glucose levels.
目的
本研究旨在评估参术调脾颗粒（SZTP）联合生活方式干预对糖耐量受损（IGT）且伴有脾虚湿盛证（SDDOS）患者的临床疗效。
方法
经过1个月的洗脱期后，共514例患者被随机分为对照组（生活方式干预）和试验组（SZTP加生活方式干预），每组257例。对照组患者接受生活方式干预（饮食和运动）12个月，而试验组患者接受SZTP加生活方式干预12个月。观察每组治疗前后的中医症状评分；还测量了IGT向糖尿病（DM）的转化率。
结果
治疗12个月后，试验组IGT向DM的转化率显著低于对照组（8.52%对15.28%，P<0.05）。试验组中IGT恢复至正常血糖水平的患者数量显著多于对照组（42.15%对32.87%，P<0.05）。此外，治疗12个月后，试验组患者的中医症状与对照组相比明显减轻（P<0.01）。
结论
SZTP与生活方式干预相结合可降低IGT向DM的转化率，并提高IGT向正常血糖水平的转化率。
Zotero 插件